oligodendrocyte

Heart Medication Digoxin Helps With Remyelination in Early Study

Digoxin, an approved medication for certain heart conditions, promoted the repair of myelinĀ ā€” the protective sheath around nerve fibers that is progressively lost in multiple sclerosis ā€” in mouse models of the disease, a study reports. Combining digoxin with an experimental immune-modulating therapy was more effective at promoting myelin…

Cholesterol Made by Nerve Cells Repairs Myelin Damage in Mice

Cholesterol made by neurons is crucial for repairing long-term damage to the myelin sheath, the fatty coating around nerve fibers that is damaged in multiple sclerosis (MS), according to a new report based on experiments done on mice. The finding suggests that increasing neuronal cholesterol synthesis may be helpful…

NeuroScientific Biopharmaceuticals’ Lead Candidate, EmtinB, Shows Promise in Preclinical Model of MS

NeuroScientific Biopharmaceuticals (NSB)ā€™s lead candidate EmtinBĀ induces significantly greaterĀ myelin regeneration in a cellular model ofĀ multiple sclerosisĀ (MS) than the market-leading therapyĀ Copaxone, the company announced. ā€œThese results represent a potential breakthrough in the treatment of MS as there are currently no approved therapeutic drugs available to patients that…

Blocking LRP1 May Halt Inflammation, Promote Remyelination, Mouse Study Suggests

Blocking production of the low-density lipoprotein receptor-related protein 1 (LRP1) ā€” involved in inflammatory and immune responses ā€” specifically in myelinĀ repair cells halts neuroinflammation and promotes myelin repair, a preclinical study shows. These results, fromĀ two mouse models of multiple sclerosis (MS), shed light on the underlying mechanisms…

NervGen to Advance NVG-291 as Potential Remyelination Therapy for MS

NervGen wants to advance the development of NVG-291, its lead investigational therapy for spinal cord damage, as a potential remyelination treatment for multiple sclerosis (MS), the company announced. Following preclinical data showing that NVG-291 promotes myelin repair and regeneration of damaged nerves in animal models of…

This Is What Excites Me About Remyelination Therapy Research

RemyelinationĀ therapies are on the horizon as an innovative multiple sclerosis (MS) treatment, according to my neurologist. These therapies have been on my radar the last few years, but to hear my neurologist say they could soon be a reality makes me hopeful of the possibilities. To offer a…

Astrocytes Can Turn Aggressive and Kill Neurons, Potentially Groundbreaking Study Says

In what may be one of the most significant discoveries in neurodegenerative disease, researchersĀ have found that brain cells, called astrocytes, contribute to killing neurons and myelin-forming oligodendrocyte cells, which may drive neurodegenerative diseases such as multiple sclerosis (MS). Experiments indicate an aggressive astrocyte type kills cells by secreting a yet-unidentified…

Myelin-Producing Brain Cells Seen for 1st Time to Be Highly Diverse and Specialized

Oligodendrocytes ā€” brain cells that wrap themselves around neurons to produce myelin ā€” are much more diverse than previously believed. ScientistsĀ in Sweden, using a newĀ type of sequencing, have discovered more thanĀ a dozen different kinds, including anĀ oligodendrocyte subtype involved in motor learning, a finding that might spur new research into protecting…

Anavex Life Sciences to Present Preclinical Data on Lead MS Drug Candidate at ACTRIMS 2016

Anavex Life Sciences, a biopharmaceutical company focused on the development of new therapies for neurodegenerative and central nervous system (CNS) diseases, among others, recently announced the presentation of preclinical data forĀ one of its lead drug candidates, ANAVEX2-73, as a multiple sclerosis (MS) treatment. The preclinical studyā€™s lead investigator, Dr.

Experimental RRMS Therapy to Be Tested in a Phase 2b Clinical Trial

GeNeuro, a company developing therapies for neurological and autoimmune disorders, recently announced the initiation of a Phase 2b clinical trial to assess its lead investigational antibody GNbAC1 in patients with relapsing-remitting multiple sclerosis (RRMS). The trial, called ā€œCHANGE-MS,ā€ plans to enroll 260 patients across 68 centers acrossĀ theĀ European Union and…